Premium
Effects of cisplatin on parathyroid hormone‐ and human lung tumor‐induced bone resorption
Author(s) -
Abramson Edith C.,
Chang Jeffry,
Mayer Marjorie,
Kukla Lawrence J.,
Shevrin Daniel H.,
Lad Thomas E.,
Buschman Robert,
Kukreja Subhash C.
Publication year - 1988
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1002/jbmr.5650030510
Subject(s) - bone resorption , calvaria , resorption , endocrinology , medicine , parathyroid hormone , osteoclast , malignancy , cisplatin , chemistry , in vitro , chemotherapy , calcium , biochemistry , receptor
We have previously shown that dichlorodiamine platinum (DDP), or cisplatin, a cancer chemotherapeutic agent, is effective in the treatment of malignancy‐associated hypercalcemia. In the present studies, we evaluated its effects on bovine parathyroid hormone (PTH)‐ or tumor‐induced bone resorption in vitro in the neonatal mouse calvarial bone resorption assay. PTH alone or tumor extract (TE) of a human squamous cell lung cancer alone caused a significant increase in the bone resorption and in the number of osteoclasts in the calvaria. The addition of 3 and 10 μg/ml DDP inhibited the PTH‐ or TE‐induced bone resorption. Lower doses of 1 and 2 μg/ml DDP, although not effective in inhibiting the PTH‐induced bone resorption, were effective in lowering the TE‐induced bone resorption. The number of osteoclasts was also reduced by DDP treatment. We therefore conclude that DDP is effective in the treatment of malignancy‐associated hypercalcemia by virtue of its inhibitory effects on osteoclast numbers and on bone resorption.